Petrescu Cristian, Mihalache Oana A, Vilciu Crisanda, Petrescu Diana M, Marian Gabriela, Ciobanu Constantin A, Ciobanu Adela M
Neuroscience Department, Discipline of Psychiatry, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Department of Psychiatry, 'Prof. Dr. Alexandru Obregia' Clinical Hospital of Psychiatry, 041914 Bucharest, Romania.
Biomedicines. 2024 Apr 3;12(4):787. doi: 10.3390/biomedicines12040787.
Schizophrenia is a severe, chronic neuropsychiatric disorder characterized by symptoms that profoundly impact behavior, cognition, perception, and emotions, leading to a reduced quality of life and physical impairment. Given the complexity of schizophrenia, there is a pressing need for clinical markers and tools to predict its course, enhance disease staging, facilitate early intervention, improve differential diagnosis, and tailor individualized treatment approaches. Previous studies focused on the relationship between neurological soft signs (NSS) and factors such as age, illness duration, and symptomatology, indicating NSS as state markers improving in parallel with psychotic symptom remission or predicting treatment resistance. However, there is a lack of consensus on NSS assessment tools, hindering routine clinical monitoring despite diagnostic and prognostic potential. The present longitudinal study involved 81 psychiatric inpatients diagnosed with schizophrenia. Patients were assessed at three time points: baseline, 1 month, and 6 months. The examination included the use of scales to evaluate psychotic and neurological symptoms, as well as the identification of adverse extrapyramidal reactions caused by neuroleptic treatment. The progression of NSS was correlated to both the symptomatology and the sociodemographic data of the patients. The main findings from the present investigation revealed a statistical correlation between NSS and psychopathological symptoms, especially with negative symptoms of schizophrenia. However, it is important to note that neuroleptic side effects only had a limited impact on NSS. Therefore, instead of being linked to extrapyramidal symptoms caused by neuroleptics, NSS appears to be more frequently related with symptoms of schizophrenia. Our findings provide further support for their strong association with the course of schizophrenia, independent of treatment side effects, thus emphasizing their potential as reliable assessment tools in both research and clinical settings.
精神分裂症是一种严重的慢性神经精神障碍,其症状会对行为、认知、感知和情绪产生深远影响,导致生活质量下降和身体损伤。鉴于精神分裂症的复杂性,迫切需要临床标志物和工具来预测其病程、完善疾病分期、促进早期干预、改善鉴别诊断并制定个性化治疗方案。以往的研究聚焦于神经软体征(NSS)与年龄、病程及症状学等因素之间的关系,表明NSS作为状态标志物会随着精神病性症状的缓解而同步改善,或可预测治疗抵抗。然而,对于NSS评估工具缺乏共识,尽管其具有诊断和预后潜力,但仍阻碍了常规临床监测。本纵向研究纳入了81例被诊断为精神分裂症的精神科住院患者。在三个时间点对患者进行评估:基线、1个月和6个月。检查包括使用量表评估精神病性和神经症状,以及识别抗精神病药物治疗引起的锥体外系不良反应。NSS的进展与患者的症状学和社会人口统计学数据相关。本调查的主要发现揭示了NSS与精神病理症状之间存在统计学关联,尤其是与精神分裂症的阴性症状。然而,需要注意的是,抗精神病药物副作用对NSS的影响有限。因此,NSS似乎更常与精神分裂症症状相关,而非与抗精神病药物引起的锥体外系症状有关。我们的研究结果进一步支持了它们与精神分裂症病程的强关联,独立于治疗副作用,从而强调了它们在研究和临床环境中作为可靠评估工具的潜力。